Patents by Inventor Hervé Da Costa

Hervé Da Costa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100150833
    Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 17, 2010
    Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
  • Publication number: 20100143253
    Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
  • Publication number: 20100143251
    Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 10, 2010
    Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
  • Patent number: 7700616
    Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: April 20, 2010
    Assignee: Molecular Neuroimaging, LLC.
    Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
  • Publication number: 20070123529
    Abstract: The invention relates to compound of formula (I) wherein: B represents hydrogen, COOR, CONRR?, or (C1-C6)alkyl substituted by COOR, CONRR?, or OR, G1 represents —X?—(CH2)n—X—(CH2)m—X?— chain wherein X, X?, X?, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G2 represents alkylene chain as defined in the description, and A represents NRCOR?, NRCSR?, CONRR?, CSNRR?, NRCONR?R?, or NRCSNR?R?. and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: May 31, 2007
    Applicant: LES LABORATOIRES SERVIER
    Inventors: Carole Descamps-Francois, Said Yous, Daniel Lesieur, Gerald Guillaumet, Marie-Claude Viaud, Herve Da-Costa, Caroline Bennejean, Philippe Delagrange, Pierre Renard
  • Patent number: 7161035
    Abstract: The invention relates to compounds of formula (I): wherein: B represents a hydrogen atom, a COOR group, a CONRR? group, or a (C1–C6)alkyl group substituted by a COOR, CONRR? or OR group, G1 represents a —X?—(CH2)n—X—(CH2)m—X?— chain wherein X, X?, X?, n and m are as defined in the description, Cy represents a grouping of formula (II) or (III): G2 represents an alkylene chain as defined in the description, and A represents a NRCOR?, NRCSR?, CONRR?, CSNRR?, NRCONR?R? or NRCSNR?R? group.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: January 9, 2007
    Assignee: Les Laboratoires Servier
    Inventors: Carole Descamps-Francois, Said Yous, Daniel Lesieur, Gérald Guillaumet, Marie-Claude Viaud, Hervé Da Costa, Caroline Bennejean, Philippe Delagrange, Pierre Renard
  • Publication number: 20040014969
    Abstract: The invention relates to compound of formula (I): 1
    Type: Application
    Filed: March 14, 2003
    Publication date: January 22, 2004
    Inventors: Carole Descamps-Francois, Said Yous, Daniel Lesieur, Gerald Guillaumet, Marie-Claude Viaud, Herve Da Costa, Caroline Bennejean, Philippe Delagranes, Pierre Renard